SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Squibb Presents First ADEPT Program Clinical Data

Bristol Myers Squibb announced preliminary findings from open-label periods of the ADEPT-1 and ADEPT-3 studies evaluating KarXT for psychosis associated with Alzheimer’s disease.

BMY

Related stories